Skip to main content
NCBI home page
Archives of Disease in Childhood logoLink to Archives of Disease in Childhood
. 2004 Aug;89(8):776–780. doi: 10.1136/adc.2003.032748

Coronary risk factors in Kawasaki disease treated with additional gammaglobulin

M Miura 1, H Ohki 1, T Tsuchihashi 1, H Yamagishi 1, Y Katada 1, K Yamada 1, Y Yamashita 1, A Sugaya 1, O Komiyama 1, H Shiro 1
PMCID: PMC1720042  PMID: 15269082

Abstract

Aims: To assess the hypothesis that an additional intravenous gammaglobulin (IVGG) infusion, if administered early, may prevent coronary artery lesions (CAL) in patients with Kawasaki disease (KD) who do not respond to initial IVGG therapy.

Methods: Forty four KD patients (17 with CAL and 27 without CAL), treated with additional IVGG because of persistent or recrudescent fever after initial IVGG therapy, were studied. Main outcome measures were the presence of CAL by echocardiography and the number of febrile days before and after start of additional IVGG infusion (pre- and post-additional IVGG).

Results: In univariate analyses, risk factors for CAL were the number of febrile days pre-additional IVGG, the number of febrile days post-additional IVGG, the number of days that initial IVGG was divided over, the white blood cell count pre- and post-additional IVGG, and the C reactive protein concentration pre-additional IVGG. In a multivariate analysis, the only independent risk factor was the number of febrile days pre-additional IVGG (⩾10 days; odds ratio 7.86; 95% CI 1.44 to 42.8; p = 0.02).

Conclusions: Among KD patients with persistent or recrudescent fever after initial IVGG therapy, administration of additional IVGG before the first 10 febrile days was associated with a decreased prevalence of CAL, when compared with the prevalence in those who were retreated later. An additional IVGG infusion, if administered early, may prevent CAL in initial IVGG non-responders.

Full Text

The Full Text of this article is available as a PDF (116.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Beiser A. S., Takahashi M., Baker A. L., Sundel R. P., Newburger J. W. A predictive instrument for coronary artery aneurysms in Kawasaki disease. US Multicenter Kawasaki Disease Study Group. Am J Cardiol. 1998 May 1;81(9):1116–1120. doi: 10.1016/s0002-9149(98)00116-7. [DOI] [PubMed] [Google Scholar]
  2. Brogan P. A., Bose A., Burgner D., Shingadia D., Tulloh R., Michie C., Klein N., Booy R., Levin M., Dillon M. J. Kawasaki disease: an evidence based approach to diagnosis, treatment, and proposals for future research. Arch Dis Child. 2002 Apr;86(4):286–290. doi: 10.1136/adc.86.4.286. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Burns J. C., Capparelli E. V., Brown J. A., Newburger J. W., Glode M. P. Intravenous gamma-globulin treatment and retreatment in Kawasaki disease. US/Canadian Kawasaki Syndrome Study Group. Pediatr Infect Dis J. 1998 Dec;17(12):1144–1148. doi: 10.1097/00006454-199812000-00009. [DOI] [PubMed] [Google Scholar]
  4. Durongpisitkul K., Soongswang J., Laohaprasitiporn D., Nana A., Prachuabmoh C., Kangkagate C. Immunoglobulin failure and retreatment in Kawasaki disease. Pediatr Cardiol. 2002 Dec 4;24(2):145–148. doi: 10.1007/s00246-002-0216-2. [DOI] [PubMed] [Google Scholar]
  5. Han R. K., Silverman E. D., Newman A., McCrindle B. W. Management and outcome of persistent or recurrent fever after initial intravenous gamma globulin therapy in acute Kawasaki disease. Arch Pediatr Adolesc Med. 2000 Jul;154(7):694–699. doi: 10.1001/archpedi.154.7.694. [DOI] [PubMed] [Google Scholar]
  6. Hashino K., Ishii M., Iemura M., Akagi T., Kato H. Re-treatment for immune globulin-resistant Kawasaki disease: a comparative study of additional immune globulin and steroid pulse therapy. Pediatr Int. 2001 Jun;43(3):211–217. doi: 10.1046/j.1442-200x.2001.01373.x. [DOI] [PubMed] [Google Scholar]
  7. Kato H. Cardiovascular involvement in Kawasaki disease: evaluation and natural history. Prog Clin Biol Res. 1987;250:277–286. [PubMed] [Google Scholar]
  8. Koren G., Lavi S., Rose V., Rowe R. Kawasaki disease: review of risk factors for coronary aneurysms. J Pediatr. 1986 Mar;108(3):388–392. doi: 10.1016/s0022-3476(86)80878-2. [DOI] [PubMed] [Google Scholar]
  9. Mori M., Imagawa T., Yasui K., Kanaya A., Yokota S. Predictors of coronary artery lesions after intravenous gamma-globulin treatment in Kawasaki disease. J Pediatr. 2000 Aug;137(2):177–180. doi: 10.1067/mpd.2000.107890. [DOI] [PubMed] [Google Scholar]
  10. Naoe S., Takahashi K., Masuda H., Tanaka N. Kawasaki disease. With particular emphasis on arterial lesions. Acta Pathol Jpn. 1991 Nov;41(11):785–797. doi: 10.1111/j.1440-1827.1991.tb01620.x. [DOI] [PubMed] [Google Scholar]
  11. Newburger J. W., Takahashi M., Beiser A. S., Burns J. C., Bastian J., Chung K. J., Colan S. D., Duffy C. E., Fulton D. R., Glode M. P. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med. 1991 Jun 6;324(23):1633–1639. doi: 10.1056/NEJM199106063242305. [DOI] [PubMed] [Google Scholar]
  12. Newburger Jane W., Taubert Kathryn A., Shulman Stanford T., Rowley Anne H., Gewitz Michael H., Takahashi Masato, McCrindle Brian W. Summary and abstracts of the Seventh International Kawasaki Disease Symposium: December 4-7, 2001, Hakone, Japan. Pediatr Res. 2003 Jan;53(1):153–157. doi: 10.1203/00006450-200301000-00026. [DOI] [PubMed] [Google Scholar]
  13. Rosenfeld E. A., Corydon K. E., Shulman S. T. Kawasaki disease in infants less than one year of age. J Pediatr. 1995 Apr;126(4):524–529. doi: 10.1016/s0022-3476(95)70344-6. [DOI] [PubMed] [Google Scholar]
  14. Rowley A. H., Shulman S. T. Kawasaki syndrome. Pediatr Clin North Am. 1999 Apr;46(2):313–329. doi: 10.1016/s0031-3955(05)70120-6. [DOI] [PubMed] [Google Scholar]
  15. Sundel R. P., Burns J. C., Baker A., Beiser A. S., Newburger J. W. Gamma globulin re-treatment in Kawasaki disease. J Pediatr. 1993 Oct;123(4):657–659. doi: 10.1016/s0022-3476(05)80972-2. [DOI] [PubMed] [Google Scholar]
  16. Tse Shirley M. L., Silverman Earl D., McCrindle Brian W., Yeung Rae S. M. Early treatment with intravenous immunoglobulin in patients with Kawasaki disease. J Pediatr. 2002 Apr;140(4):450–455. doi: 10.1067/mpd.2002.122469. [DOI] [PubMed] [Google Scholar]
  17. Wallace C. A., French J. W., Kahn S. J., Sherry D. D. Initial intravenous gammaglobulin treatment failure in Kawasaki disease. Pediatrics. 2000 Jun;105(6):E78–E78. doi: 10.1542/peds.105.6.e78. [DOI] [PubMed] [Google Scholar]
  18. Zaitsu M., Hamasaki Y., Tashiro K., Matsuo M., Ichimaru T., Fujita I., Tasaki H., Miyazaki S. Ulinastatin, an elastase inhibitor, inhibits the increased mRNA expression of prostaglandin H2 synthase-type 2 in Kawasaki disease. J Infect Dis. 2000 Mar;181(3):1101–1109. doi: 10.1086/315332. [DOI] [PubMed] [Google Scholar]
  19. de Zorzi A., Colan S. D., Gauvreau K., Baker A. L., Sundel R. P., Newburger J. W. Coronary artery dimensions may be misclassified as normal in Kawasaki disease. J Pediatr. 1998 Aug;133(2):254–258. doi: 10.1016/s0022-3476(98)70229-x. [DOI] [PubMed] [Google Scholar]

Articles from Archives of Disease in Childhood are provided here courtesy of BMJ Publishing Group

RESOURCES